title: Hematopoietic cell culture therapies (Part II): Clinical aspects and applications.
abstract: High-dose chemotherapy, followed by hematopoietic stem cell transplantation, holds significant promise for increasing the probability of long-term remission and possibly cure in a variety of cancers. Hematopoietic cell culture, or ex vivo expansion of hematopoietic cells, may play a significant role in reducing the danger and expense associated with the transplantation procedure. Phase I clinical trials have shown that ex vivo expanded cells have no significant toxicities, and some benefits. Ex vivo expansion of hematopoietic cells is likely to find other applications in gene therapy, tumor purging, production of dendritic cells for immunotherapy and the production of mature blood cells for transfusion therapies.
authors.affiliation: Department of Chemical Engineering, Northwestern University, Evanston, IL 60208-3120, USA.
authors.forename: T A
authors.initials: TA
authors.lastname: McAdams
authors.forename: J N
authors.initials: JN
authors.lastname: Winter
authors.forename: W M
authors.initials: WM
authors.lastname: Miller
authors.forename: E T
authors.initials: ET
authors.lastname: Papoutsakis
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism; D001709:Biotechnology / Q000639:trends; D016026:Bone Marrow Transplantation; D002478:Cells, Cultured; D002986:Clinical Trials as Topic / Q000639:trends; D003131:Combined Modality Therapy; D005312:Fetal Blood / Q000166:cytology; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000639:trends*; D006413:Hematopoietic System / Q000166:cytology* / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000628:therapy
chemical_list: D018952:Antigens, CD34